FLT3 and acute myeloid leukemia: These mutations represent an issue in AML since FLT3-ITD-mutated cells, although chemosensitive at diagnosis and responsive to initial chemotherapy, lead to relapse in a substantial number of patients especially those who have not received allo-SCT.